Bridge-Helix Cap Target Inhibits Bacterial RNA Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bacterial infections caused by multi-drug-resistant bacteria pose a growing threat due to antibiotic resistance, necessitating new approaches for drug development that target bacterial RNA polymerase effectively without inducing cross-resistance with existing antibiotics.
Innovation Solution
Salinamide A (Sal) is identified as an inhibitor of bacterial RNA polymerase, targeting specific residues that confer resistance, allowing for its use in combination with other antibiotics to minimize resistance emergence, and a new target, the 'bridge-helix cap target', is defined for antibacterial drug discovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently used antibiotics are administered, then bacterial infections are treated, but antibiotic resistance develops leading to treatment failure
Solution Approach 1:
The patent segments the RNA polymerase target into two distinct binding sites: the traditional rifamycin binding site and the novel bridge-helix cap site. By targeting a separate, non-overlapping region (residues 690, 697, 758, 763 of β′ subunit and residues 561, 569, 665, 675, 677, 680 of β subunit), salinamide A prevents bacteria from developing cross-resistance to rifamycins, thus maintaining treatment effectiveness while avoiding the adaptability issue of resistance development.
Solution Approach 2:
Salinamide A acts as an intermediary compound that bridges the gap between existing antibiotic classes and novel mechanisms. It binds to the bridge-helix cap region of RNA polymerase, which is structurally distinct from rifamycin binding sites, thereby providing a new therapeutic avenue that mediates antibacterial activity without cross-resistance. This intermediary approach allows combination therapy with rifamycins to suppress resistance emergence.
2Adaptability or versatility
If new antibiotic targets are identified, then cross-resistance is reduced, but the complexity of drug development increases
Solution Approach 1:
The bridge-helix cap target identified in this patent represents a universal binding site across bacterial RNA polymerases that is distinct from rifamycin sites. By establishing this new target paradigm, the patent enables multiple salinamide derivatives to be developed with improved pharmacokinetic and pharmacodynamic properties while maintaining the same resistance-breaking mechanism. This universal target approach simplifies subsequent drug development compared to searching for entirely new targets.
Solution Approach 2:
The patent performs preliminary identification and characterization of the bridge-helix cap target before full-scale drug development. By mapping the specific residues (690, 697, 758, 763 of β′ and 561, 569, 665, 675, 677, 680 of β) and confirming their non-overlap with rifamycin sites, the patent lays the groundwork for future drug development, reducing the complexity of subsequent steps while establishing the cross-resistance advantage early in the process.
3Reliability
If combination therapy is used, then resistance emergence is suppressed, but treatment complexity increases
Solution Approach 1:
The patent converts the potential harm of requiring combination therapy into a benefit by demonstrating that salinamide A's unique bridge-helix cap targeting mechanism naturally suppresses resistance when combined with rifamycins. The non-overlapping binding sites mean that resistance mutations beneficial for rifamycin resistance do not confer cross-resistance to salinamide, and vice versa. This transforms the complexity of combination therapy into a reliable resistance suppression strategy, where the two drugs work synergistically rather than competitively.
Data Source
AI summary
It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance.